Anti-EGFR Monoclonal Antibody SCT200 clinical trials
Also written SCT200.
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2015
How each study uses Anti-EGFR Monoclonal Antibody SCT200 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- SCT200
- 7
Studies by the year they started
7 studies that test it; most in 2018 (3)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2018 | 3 |
| 2019 | 2 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Anti-EGFR Monoclonal Antibody SCT200 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- SCT200 Plus Platinum-based Chemotherapy in Head and Neck Squamous Cell CarcinomaStatus unknownPhase 2Sinocelltech Ltd.NCT03874741Written as SCT200
- Study of SCT-I10A Combined SCT200 or SCT-I10A Combined SCT200 Plus Chemotherapy in ESCC and CRCStatus unknownPhase 1Sinocelltech Ltd.NCT04229537Written as SCT200
- Safety and Efficacy of SCT200 in Patients With Advanced Esophageal Squamous Cell CarcinomaStatus unknownPhase 1/2Sinocelltech Ltd.NCT03817567Written as recombinant anti-EGFR monoclonal antibody
- Efficacy and Safety of SCT200 in Patients With Advanced Squamous Non-small Cell Lung CancerStatus unknownPhase 1Sinocelltech Ltd.NCT03808701Written as SCT200
- Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SCT200 in Patients With Advanced Solid TumorsStatus unknownPhase 1Sinocelltech Ltd.NCT03692520Written as SCT200
- Safety and Efficacy of SCT200 in Patients With Relapsed or Metastatic Triple Receptor Negative Breast CancerStatus unknownPhase 2Sinocelltech Ltd.NCT03692689Written as SCT200
- Safety, Tolerability and Pharmacokinetics of Recombinant Anti-epidermal Growth Factor Receptor(EGFR) Monoclonal Antibody in Patients With Metastatic Colorectal CancerStatus unknownPhase 1Sinocelltech Ltd.NCT02211443Written as Recombinant full human Anti-EGFR Monoclonal Antibody